Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
10Customers
1Debt Items
20Related Chains
Source-Backed Evidence Depth
Immutep Limited (IMMP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
17Total relationships
2Distinct source URLs
6High confidence
0.756Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Immutep Limited Suppliers
Ticker
Name
Confidence
Evidence
EOC-PHARMA
EOC-PHARMA
90%
Immutep retains development and commercialization rights of efti (designated EOC202) in all other territories except China, Hong Kong, Macau and Taiwan to EOC Pharma.
Reciprocal relationship from MRK graph: Reciprocal relationship from IMMP graph: Reciprocal relationship from MRK graph: Reciprocal relationship from IMMP graph: Reciprocal relationship from MRK grap…
Reciprocal relationship from PRRUF graph: Reciprocal relationship from IMMP graph: Reciprocal relationship from PRRUF graph: Reciprocal relationship from IMMP graph: Reciprocal relationship from PRRU…
Reciprocal relationship from RDY graph: Reciprocal relationship from IMMP graph: Reciprocal relationship from RDY graph: Reciprocal relationship from IMMP graph: Reciprocal relationship from RDY grap…
Reciprocal relationship from HYFT graph: Reciprocal relationship from IMMP graph: Reciprocal relationship from HYFT graph: ancing activities: Proceeds from share issuance, net of transaction costs 12…
Immutep Limited Customers
Ticker
Name
Confidence
Evidence
LABORATORY-CORPORATION-OF-AMERICA-HOLDINGS
LABORATORY-CORPORATION-OF-AMERICA-HOLDINGS
92%
Immutep received initial fees from LabCorp in fiscal year 2021 and may be eligible to receive further revenues from commercial milestones as the collaboration progresses under its 2020 License and Co…
MERCK-CO-INC
MERCK-CO-INC
92%
In June 2024, Immutep entered into its third and most important collaboration with Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) for the registrational Phase …
EOC-PHARMA
EOC-PHARMA
90%
Immutep granted development and commercialization rights of efti (designated EOC202) in China, Hong Kong, Macau and Taiwan to EOC Pharma.
ure as more patients are recruited to our clinical trials. In particular, we expect to continue to incur significant losses in carrying out clinical trials of efti and IMP761 as well as from ongoing …
Reciprocal relationship from MRK graph: Reciprocal relationship from IMMP graph: ure as more patients are recruited to our clinical trials. In particular, we expect to continue to incur significant l…
Reciprocal relationship from PRRUF graph: . 28 Table of Contents IMP761 Preclinical Development On January 3, 2017 we announced a new early stage product candidate to be known as IMP761, developed in…
DELAWARE-UNITED-STATES-IMMUTEP-GMBH
DELAWARE-UNITED-STATES-IMMUTEP-GMBH
62%
nd first-in-human Phase I study evaluating IMP761. In June 2025, Immutep announced initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppressio…
FORMATION-ACQUISITION-JURISDICTION-IMMUTEP-U-S-I
FORMATION-ACQUISITION-JURISDICTION-IMMUTEP-U-S-I
62%
nd first-in-human Phase I study evaluating IMP761. In June 2025, Immutep announced initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppressio…
GERMANY-IMMUTEP-AUSTRALIA-PTY-LTD
GERMANY-IMMUTEP-AUSTRALIA-PTY-LTD
62%
nd first-in-human Phase I study evaluating IMP761. In June 2025, Immutep announced initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppressio…
PRR-MIDDLE-EAST-FZ-LLC
PRR-MIDDLE-EAST-FZ-LLC
62%
NOTE 24. REMUNERATION OF AUDITORS During the year the following fees were paid or payable for services provided by the auditor of the parent entity, its related practices and non-related audit firms.…
Immutep Limited Debt Obligations
Instrument
Description
Confidence
Evidence
IMMP-DEBT
Debt stack $865,240
90%
Market cache reports total debt of $865,240.
Immutep Limited Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Immutep Limited.
Immutep Limited Ownership
Holder
Name
Confidence
Evidence
IMMP-OWNER-BLACKROCK-INC
Blackrock Inc.
90%
13F overlay lists Blackrock Inc. as top holder; 10 tracked holders.
